



15 November 2024

LungLife AI, Inc.  
(the "Company" or "LungLife")

**Block Listing Six Monthly Return**

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of applicant:	LungLife AI, Inc.		
Name of scheme:	1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan		
Number and class of securities originally admitted:	1,356,139 common shares of US \$0.0001 each		
Date of admission:	15 November 2021		
Period of return:	From:	15 May 2024	To: 15 November 2024
Balance of unallotted securities under scheme(s) from previous return:	1. 475,583 2. 201,374 3. 673,990		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	1. NIL 2. NIL 3. NIL		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	1. NIL 2. NIL 3. NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	1. 475,583 2. 201,374 3. 673,990		
Total number of securities in issue at the end of the period	30,658,603		

Name of contact:	David Anderson, Chief Financial Officer
Telephone number of contact:	+44 (0)20 7933 8780

**For further information please contact:**

LungLife AI, Inc.  
Paul Pagano, CEO

[www.lunglifeai.com](http://www.lunglifeai.com)  
via [investors@lunglifeai.com](mailto:investors@lunglifeai.com)

David Anderson, CFO

**Investec Bank plc (Nominated Adviser & Broker)**

Virginia Bull / Lydia Zychowska / Sara Wallace

**Tel: +44 (0)20 7597 5970**

**Goodbody (Joint Broker)**

Tom Nicholson / Cameron Duncan

**Tel: +44 (0) 20 3841 6202**

**About LungLife**

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB<sup>®</sup> test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit [www.lunglifeai.com](http://www.lunglifeai.com)

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.